Neopterin and Beta-2 Microglobulin Relations to Immunity and Inflammatory Status in Nonischemic Dilated Cardiomyopathy Patients

Table 2

Serum concentrations of immune activation and inflammatory markers in all DCM patients, group A, group B, and control, median (25th–75th percentiles).

	All DCM; = 169	Group A; = 46	Group B; = 123	A versus B	Group C; = 30	A versus C*; B versus C**
NPT; nmol/L	5.78; (3.27–12.48)	8.11; (4.50–12.57)	5.36; (2.97–12.77)	ns	4.99; (2.66–8.28)	<0.05*; ns**
-2 M; mg/L	2.53; (1.63–3.71)	2.60; (1.71–3.58)	2.52; (1.51–3.72)	ns	1.75; (1.28–1.96)	<0.001*; <0.0001**
hsCRP; mg/L	4.52; (2.30–7.00)	4.84; (1.50–7.11)	4.54; (2.48–6.94)	ns	—	—
Fibrinogen; mg/dL	327.0; (279–392)	328.0; (283–390)	327; (298–372)	ns	—	—